Koyfin Home > Directory > Health Care > Anika Therapeutics > EBITDA

Anika Therapeutics EBITDA Chart (ANIK)

Anika Therapeutics annual/quarterly EBITDA from 2010 to 2020. EBITDA stands for earnings before interest, taxes, depreciation and amortization. EBITDA is one indicator of a company's financial performance and is used as a proxy for the earning potential of a business, although doing so can have drawbacks. EBITDA strips out the cost of debt capital and its tax effects by adding back interest and taxes to earnings.
  • Anika Therapeutics EBITDA for the quarter ending June 06, 2020 was $0m a -5,157.75% decrease of -13m year over year
  • Anika Therapeutics EBITDA for the last 12 months ending June 06, 2020 was $32m a -33.65% decrease of -11m year over year
  • Anika Therapeutics Annual EBITDA for 2019 was $43m a 22.14% increase of 10m from 2018
  • Anika Therapeutics Annual EBITDA for 2018 was $34m a -47.73% decrease of -16m from 2017
  • Anika Therapeutics Annual EBITDA for 2017 was $50m a -8.64% decrease of -4m from 2016
Other Income Statement Metrics:
  • Anika Therapeutics Net Income for the quarter ending December 12, 2018 was $8m a 186.64% increase of 14m year over year
  • Anika Therapeutics Total Revenue for the quarter ending December 12, 2018 was $27m a 21.12% increase of 6m year over year
View Chart On Koyfin

Quarterly ANIK EBITDA Data

06/2020$0m
03/2020$8m
12/2019$9m
09/2019$14m
06/2019$13m
03/2019$7m
12/2018$9m
09/2018$10m
06/2018$13m
03/2018$0m

Annual ANIK EBITDA Data

2019$43m
2018$34m
2017$50m
2016$54m
2015$53m
2014$66m
2013$37m
2012$27m
2011$18m
2010$11m